Research roundup: Docs' views of industry gifts; Chemotherapy payments; Health law an

[gdpawel]

There is a very strong bias in the U.S. medical community towards chemotherapy/targeted therapy over hormonal therapy. I understand Europeans are more inclined to treat patients with hormonal therapy that American oncologists would treat with chemo. Another factor has been the lucrative reimbursement policies that U.S. oncologists get for using chemotherapy/targeted therapy as opposed to hormonal treatment or even to give no drug treatment. Will physicians and their patients consider Oncotype Dx or MammaPrint to forgo both chemotherapy/targeted therapy and hormonal therapy? Sometimes you're forced to go with the flow.